HOME >> MEDICINE >> NEWS
Tamoxifen for prevention of breast cancer encouraging results but risks still unclear

Early findings from a randomised trial investigating the effectiveness of tamoxifen to prevent breast cancer are reported in this week's issue of THE LANCET. Although tamoxifen reduced breast cancer incidence by a third compared with women given placebo, the authors of the study caution that it is still too early to fully assess the risk to benefit ratio of tamoxifen as a preventative strategy for breast cancer.

Tamoxifen is well known in its effect to decrease recurrence of (and death from) breast cancer; however, three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side-effects associated with tamoxifen is unclear.

Jack Cuzick from Cancer Research UK, lead investigator of the International Breast Cancer Intervention Study (IBIS-I) and colleagues undertook a double-blind placebo-controlled randomised trial of tamoxifen, 20 mg/day for 5 years, in around 7000 women from the UK, Europe, Australia and New Zealand who were aged 3570 years and who were at an increased risk of breast cancer (eg. They had a Family history of the disease or had a benign lesion associated with an increased risk of breast cancer).

The frequency of breast cancer was reduced by a third among Women given tamoxifen (69 breast cancers in 3578 women in the tamoxifen group and 101 breast cancers in 3566 in the placebo group). Endometrial cancer--considered to be increased by tamoxifen use--was doubled in the tamoxifen group (11 instances compared with 5 in the control group), but this increase was not statistically significant, and all cases were localised (stage 1) and curable by hysterectomy.

However, tamoxifen use was associated with more than a doubling in the risk of blood-clotting complications, especially after surgery or long periods of immobilisation. The investigators comment that the incre
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
12-Sep-2002


Page: 1 2

Related medicine news :

1. Tamoxifens risks similar in African American and white women
2. Tamoxifen and estrogen have similar effects on the brain
3. Tamoxifen found to increase risk of endometrial cancer
4. Views Of Tamoxifen And Synthetic Estrogen In Action Provide Clues For Designing Better Drugs
5. International breast cancer prevention study launches in the United States and Canada
6. Cavity prevention tips for pre-school age children
7. HIV and ID doctors oppose ideologically driven STI prevention policies
8. School-based smoking prevention programs ineffective
9. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
10. Mount Sinai stroke prevention trial published in JAMA
11. New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/25/2017)... ... July 25, 2017 , ... Dr. ... Arbor University recently co-authored and published an article in the medical science journal ... Plexus Palsy. Both the article and the research that helped produce it, were ...
(Date:7/25/2017)... ... 25, 2017 , ... Dr. Gina Negrette, a skilled Wisconsin-based ... a decade of experience in psychiatry, treating clients in diverse settings, including inpatient ... psychotic and manic conditions, as well as those who were fighting simply to ...
(Date:7/25/2017)... Fort Worth, Texas (PRWEB) , ... July 25, ... ... a 2017 Gold Winner for its Product Innovation in the prestigious CEO World ... leadership, innovation, organizational performance, new products and services, CEO case studies, corporate social ...
(Date:7/24/2017)... COLLEGE PARK (PRWEB) , ... July 24, 2017 , ... ... It is bio-compatible, because it produces the same kind of electrical energy that the ... in the form of moving electrons. This flow of electrons out of the battery ...
(Date:7/24/2017)... City, MO (PRWEB) , ... July 24, 2017 , ... ... the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, ... program to patients who suffer from painful intercourse and other painful pelvic ... vaginal atrophy due to menopause. ... VuVatech LLC ... created by Sarasota, Florida -based start-up company, VuVatech LLC, ...
Breaking Medicine Technology:
Cached News: